The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and prescription drug programs for contract year 2026.
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and ...
If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...
Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said. Amgen ...
The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.
CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...
The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.
A row is brewing between the White House and Robert F Kennedy Jr after the Biden administration proposed making millions of ...
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and $11 billion for Medicaid over a decade. Total Medicare drug spending over ...
Congress has been considering bipartisan solutions to help address the growing obesity problem for over a decade now.
The Biden administration on Tuesday proposed expanding drug coverage under Medicare and Medicaid to include anti-obesity ...
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...